Ocrelizumab

Where the papers sit

13 papers from the last 6 months study ocrelizumab directly · updated from PubMed 10 Oct 2026

• Clinical Monitoring in Multiple Sclerosis

  MRI is central to diagnosis, surveillance, and decisions about ongoing disease activity in multiple sclerosis. Annual monitoring during ocrelizumab treatment is being weighed against its number needed to scan, while real-world studies assess relapse control and safety. Pregnancy and postpartum disease activity remain important gaps, with comparisons involving rituximab. Natalizumab may offer better relapse outcomes and lower healthcare use than ocrelizumab in treatment-naive patients, keeping treatment selection unresolved.

  5 papers · 38.5%

• B-Cell Repopulation after Therapy

  B-cell repopulation is becoming a focus for predicting response and timing repeat anti-CD20 treatment in multiple sclerosis. CD19 and CD20 kinetics, immunoglobulin levels, and peripheral immune counts recur as practical monitoring measures. FCGR3A variation and baseline clinical features may explain differences in repopulation, while IL-6 is being tested as an outcome biomarker. Pharmacokinetic-pharmacodynamic models point toward more individualized dosing, but validated treatment thresholds remain open.

  5 papers · 38.5%

• Anti-CD20 Therapy Across Multiple Sclerosis

  Anti-CD20 treatment is being evaluated across relapsing and primary progressive multiple sclerosis, including older people and those with advanced disability. Higher bodyweight-adjusted ocrelizumab dosing is under study, extending dose optimization beyond standard regimens. Evidence continues to address whether benefit and safety persist in less typical primary progressive populations. Direct comparison with rituximab in newly diagnosed relapsing disease keeps comparative effectiveness and treatment choice in view.

  3 papers · 23.1%